← Back to Portfolio

Paratek Pharmaceuticals

Paratek is developing novel antibiotics based upon its expertise in tetracycline chemistry. The company was formed from a reverse merger with Nasdaq-listed Transcept Pharmaceuticals and Abingworth Partner, Michael Bigham, joined the combined company as Chairman and CEO. Paratek is a VIPE (Venture Investment in Private Equity). The company's lead product is a new broad-spectrum antibiotic in Phase III being developed in both oral and intravenous formulations for serious community-acquired bacterial infections.

LocationBoston, Massachusetts
CEOMichael Bigham